Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 34.5% in August

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP – Get Free Report) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totaling 43,251 shares, a decrease of 34.5% from the August 15th total of 66,082 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average daily trading volume, of 23,843 shares, the short-interest ratio is presently 1.8 days.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Aspire Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Get Aspire Biopharma alerts:

Check Out Our Latest Report on ASBP

Aspire Biopharma Price Performance

ASBP stock opened at $9.06 on Friday. The company’s 50-day moving average is $7.69 and its 200-day moving average is $12.50. The stock has a market capitalization of $12.71 million, a PE ratio of -0.13 and a beta of 0.17. Aspire Biopharma has a 1 year low of $3.31 and a 1 year high of $562.92.

Aspire Biopharma Company Profile

(Get Free Report)

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.

Further Reading

• Five stocks we like better than Aspire Biopharma
• 3 Nimble Free Cash Flow Names With Light Assets
• Intel’s Ohio Lifeline? Why the SK Hynix Talks Matter
• Generac Plugs into Amazon for an $8B AI-Powered Deal
• Laser Focus: 2 Optical Stocks Lighting Up AI

Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.